PCSK9
Amgen wins high-profile cholesterol drug patent case v Sanofi
March 17, 2016Sales and Marketing Amgen, PCSK9, Regeneron, Repatha, Sanofi, cholesterol, praluent
A Delaware district court jury has ruled in favour of Amgen in an ongoing dispute around patents for cholesterol-lowering drugs …
FDA and EMA approve heart drug Praluent
July 27, 2015Sales and Marketing EMA, FDA, PCSK9, Regeneron, Sanofi, high cholesterol, praluent
The FDA and the EMA have both approved Sanofi and Regeneron’s new high cholesterol drug Praluent. Regulators on both sides …
Pfizer launches cardiovascular research competition
April 10, 2015Research and Development, Sales and Marketing Amgen, Astellas, LDL, PCSK9, Pfizer, bococizumab, inhibitors
Pfizer is funding a new competitive grants programme to support research projects in the burgeoning, competitive area of cholesterol-lowering PCSK9 …
Sanofi and Amgen cholesterol drugs shine
March 16, 2015Sales and Marketing Amgen, PCSK9, Repatha, Sanofi, alirocumab, evolocumab, praluent
Two large Phase III studies of Sanofi’s Praluent and Amgen’s Repatha have found the biologic cholesterol-lowering drugs are more effective …
Sanofi showcases alirocumab at AHA
November 20, 2014Sales and Marketing Amgen, PCSK9, Regeneron, Sanofi, aha, alirocumab, evolocumab
Sanofi and Regeneron released a battery of new Phase III data on their PCSK9 inhibitor alirocumab this week, reinforcing the …
Amgen submits next gen cholesterol drug
August 29, 2014Sales and Marketing Amgen, FDA, PCSK9, Regeneron, Sanofi, statins
Amgen has put itself in pole position in the race to market the next generation of injectable statins known as …
Success for Amgen’s ‘bad’ cholesterol injection
March 18, 2014Research and Development, Sales and Marketing Amgen, LDL, PCSK9, evolocumab, hofh, tesla
An investigational PCSK9 Inhibitor from Amgen has reduced LDL-C (‘bad’ cholesterol) in patients suffering from a rare genetic disorder in …
